MedTrace Logo

Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT01453504 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2019-11-08

No results posted yet for this study

Summary

The purpose of this trial is

1. to determine the recommended dose of everolimus for a subsequent Phase II trial
2. to determine the efficacy of everolimus plus DHAP

Conditions

Interventions

DRUG

DHAP

Dexamethasone, Cytarabine, Cisplatin

DRUG

Everolimus

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Peter Borchmann, Prof. · University of Cologne, German Hodgkin Study Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01453504 on ClinicalTrials.gov